J 2024

Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis

MAYEROVA, Lucie, Peter WOHLFAHRT, Milan SONKA, Zhi CHEN, Josef KAUTZNER et. al.

Basic information

Original name

Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis

Authors

MAYEROVA, Lucie (203 Czech Republic), Peter WOHLFAHRT (203 Czech Republic), Milan SONKA (203 Czech Republic), Zhi CHEN, Josef KAUTZNER (203 Czech Republic), Vojtech MELENOVSKY (203 Czech Republic), Vladimir KARMAZIN (203 Czech Republic), Ivan MALEK (203 Czech Republic), Helena BEDANOVA (203 Czech Republic), Ales TOMASEK (203 Czech Republic), Eva OZÁBALOVÁ (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Tomas KOVARNIK (203 Czech Republic) and Michal PAZDERNIK (203 Czech Republic)

Edition

CLINICAL TRANSPLANTATION, HOBOKEN, WILEY, 2024, 0902-0063

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.100 in 2022

Organization unit

Faculty of Medicine

UT WoS

001183729600001

Keywords in English

acetylsalicylic acid; cardiac allograft vasculopathy; lipid plaque; OCT

Tags

Tags

International impact, Reviewed
Změněno: 10/6/2024 13:29, Mgr. Tereza Miškechová

Abstract

V originále

BackgroundThere is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV).MethodsA nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors.ResultsIn total, 175 patients (mean age 52 +/- 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699)ConclusionThis study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.